Oxymetazoline 0.05% nasal spray

Topical interventions for rosacea are often used to relieve local symptoms. However, currently, there are few articles to systematically analyze the efficacy profile of topical drugs for rosacea. This study aimed to investigate the efficacy profile of widely used topical drugs. To acquire appropriate information from related literature, we looked into 4 databases. Efficacy was appraised with the Investigator Global Assessment, Clinician's Erythema Assessment, Patient's Self-Assessment and Subject Self-Assessment of Rosacea Facial Redness scales. Treatment-emergent adverse events and dermal tolerability were also recorded. According to 21 randomized controlled trials included, a total of 6 topical drugs including minocycline, ivermectin, azelaic acid, metronidazole, brimonidine and oxymetazoline were reported. These drugs are well-tolerated and safe. Ivermectin is more effective than azelaic acid and metronidazole. Azelaic acid has a better efficacy profile than metronidazole according to included studies. Minocycline turned out to be effective improving the symptoms of rosacea. Brimonidine and oxymetazoline both have significant effects on reducing facial redness.

Abstract licence: CC BY-NC-ND

ObjectiveOxymetazoline hydrochloride has been shown to be effective in some studies for acquired blepharoptosis and for aesthetic upper eyelid elevation. This study aims to systematically review the literature on the use of topical oxymetazoline for treating acquired blepharoptosis.Databases ReviewedPubMed (U.S. National Library of Medicine, National Institutes of Health), Scopus (Elsevier), and Cochrane.MethodsA systematic review of studies published between 2013 and 2024 following PRISMA guidelines was performed using the PubMed, Scopus, and Cochrane databases. Primary outcomes included pre‐ to posttreatment change in marginal reflex distance (MRD1) after treatment with topical oxymetazoline, and mean difference (pre‐to‐posttreatment) in MRD1 versus control.ResultsFive articles included data from 458 patients for analysis. Meta‐analysis demonstrated significant improvement in MRD1 measurements posttreatment with oxymetazoline (1.40 mm; 95% confidence interval, CI [0.41 mm, 2.40 mm]). In addition, when compared to controls, patients treated with oxymetazoline demonstrated greater increase in MRD1 values (0.83 mm; 95% CI [0.10 mm, 1.55 mmm]). Heterogeneity, measured by I2 statistic, was high in all studies (85%–95%).ConclusionThe use of oxymetazoline 0.1% ophthalmic solution significantly improves MRD1 in patients with acquired blepharoptosis. Further studies comparing this treatment in other etiologies of acquired blepharoptosis should be conducted. Laryngoscope, 2024

Abstract licence: CC BY-NC 4.0

Background and objectivesRosacea is a chronic inflammatory condition affecting the central face. While laser and energy-based devices (EBDs) are commonly used for managing vascular symptoms, comprehensive comparisons between systems are limited. This study aims to evaluate and compare the efficacy and safety of lasers and EBDs for rosacea through a systematic review and network meta-analysis (NMA).MethodsRandomized controlled trials (RCTs) were identified from MEDLINE, CENTRAL, and Web of Science, with additional searches for ongoing trials. Primary outcomes included patient satisfaction, improvements in erythema and telangiectasia, and long-term adverse events (AEs). Risk of bias (RoB) and publication bias were also assessed.Results25 RCTs were included for qualitative analysis, and subsets contributed to the NMAs. Most studies exhibited unclear or high risk of bias, with a slight publication bias observed. Radiofrequency microneedling was more effective than pulsed dye laser (PDL) in terms of patient satisfaction (MD -1.32; 95 % CI -1.89 to -0.76) and erythema (MD -1.44; 95 % CI -1.96 to -0.91). The combination of oxymetazoline and PDL appeared superior for telangiectasia (MD -0.58; 95 % CI -1.03 to -0.14). AEs and discontinuation rates were comparable across treatments.

Abstract licence: CC BY

ABSTRACT Objective The objective of this systematic review is to assess the impact of oxymetazoline in patients with moderate to severe rosacea. Data Sources We will conduct a comprehensive search in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Lilacs, the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, US National Institutes of Health (NIH) and grey literature, to identify all relevant randomized controlled trials regardless of language or publication status (published, unpublished, in press and in progress). Eligibility criteria for selecting studies and methods We will include randomized trials evaluating the effect of oxymetazoline in patients with moderate to severe rosacea. Two reviewers will independently screen each study for eligibility, data extraction, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE [1] system to assess the certainty of the evidence for each outcome. Ethics and Dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media. Protocol and Registration This protocol was adapted to the specificities of the question assessed in this review and registered to PROSPERO with the ID CRD42020150262.

Abstract licence: CC BY-NC-ND